MLKL and neoplasm: Hoecke et al. (Van Hoecke et al., 2018) confirmed the direct intratumoral delivery of MLKL-mRNA coding could rapidly induce CD4+ T cells to prevent tumor progression, and this process depends on Type I interferon signaling and Batf3-dependent dendritic cells.